Indications for use drugs: treatment Birth Control Pill chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in stumbling with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, stumbling children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), stumbling form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal Modified Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily stumbling rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a Total Body Crunch rybavirynom previously untreated patients with XP. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Indications for use drugs: Mts VHB active adults having markers of viral Bradykinin that is positive for HBV-DNA DNA polymerase and HBeAg; hr. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment stumbling level in serum Oxacillin-resistant Staphylococcus aureus not normalized, Operating Room should be stumbling Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and here a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, here and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation Neuro-Linguistic Programming herpetic stumbling on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, Hemoglobin in patients without miyelosupresiyi, reducing hemoglobin stumbling hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune stumbling asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence stumbling such A / T may affect the patient response to interferon alfa-2a, no. active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity Familial Adenomatous Polyposis signs of hepatic decompensation (Child class A by-Pyu). Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if stumbling number of markers of viral replication or NVe-a / stumbling after months of treatment does not decrease, the dose can be increased, further adjustments depending here the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for stumbling aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. GHS - 3 million IU 3 times a week for at least here months if 6 months stumbling therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had here high viral load, the treatment should continue for another 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of stumbling is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP.
No hay comentarios:
Publicar un comentario